. Author manuscript; available in PMC: 2009 Jul 1.

Published in final edited form as: Vascul Pharmacol. 2008 Apr 3;49(1):6–13. doi: 10.1016/j.vph.2008.03.005

Table 2.

Maximum contraction and estimated EC₅₀ values for ET-1 (10 pM – 100 nM) - induced contraction in rat thoracic aorta and vena cava under control conditions, ET_A receptor blockade, ET_B receptor blockade and ET_A plus ET_B receptor blockade.

	Aorta		Vena cava

Treatment	Max contraction [% PE (10 μM)]	EC₅₀ (nM)	Max contraction [% NE (10 μM)]	EC₅₀ (nM)
Vehicle	120±7	7.32±0.70	481±89	9.70±2.66 ^†
Atrasentan (10 nM)	128±19 ^†	53.12±20.19^* ^†	336±28^* ^†	16.84±3.02^* ^†
BQ-788 (100 nM)	158±13^*	4.97±0.78^*	587±51	3.76±1.17^*
Atrasentan (10 nM) + BQ-788 (100 nM)	107±11 ^†	52.84±12.03^* ^†	235±39^* ^†	41.71±15.12^* ^†

Data are represented as mean ± S.E.M. Atrasentan, ETA receptor antagonist; BQ-788, ETB receptor antagonist; NE, norepinephrine; PE, phenylephrine.

represents a statistically significant difference from control (p<0.05)

^†

represents a statistically significant difference from BQ-788 (p<0.05).